PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Reinke, P.Y.A.* ; de Souza, E.E.* ; Gunther, S.* ; Falke, S.* ; Lieske, J.* ; Ewert, W.* ; Loboda, J.* ; Herrmann, A. ; Rahmani Mashhour, A.* ; Karničar, K.* ; Usenik, A.* ; Lindič, N.* ; Sekirnik, A.* ; Botosso, V.F.* ; Santelli, G.M.M.* ; Kapronezai, J.* ; de Araújo, M.V.* ; Silva-Pereira, T.T.* ; Filho, A.F.S.* ; Tavares, M.S.* ; Flórez-Álvarez, L.* ; de Oliveira, D.B.L.* ; Durigon, E.L.* ; Giaretta, P.R.* ; Heinemann, M.B.* ; Hauser, M.* ; Seychell, B.* ; Böhler, H.* ; Rut, W.* ; Drag, M.* ; Beck, T.* ; Cox, R.* ; Chapman, H.N.* ; Betzel, C.* ; Brehm, W.* ; Hinrichs, W.* ; Ebert, G. ; Latham, S.L.* ; Guimarães, A.M.S.* ; Turk, D.* ; Wrenger, C.* ; Meents, A.*

Calpeptin is a potent cathepsin inhibitor and drug candidate for SARS-CoV-2 infections.

Comm. Biol. 6:1058 (2023)
Publ. Version/Full Text DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Several drug screening campaigns identified Calpeptin as a drug candidate against SARS-CoV-2. Initially reported to target the viral main protease (Mpro), its moderate activity in Mpro inhibition assays hints at a second target. Indeed, we show that Calpeptin is an extremely potent cysteine cathepsin inhibitor, a finding additionally supported by X-ray crystallography. Cell infection assays proved Calpeptin's efficacy against SARS-CoV-2. Treatment of SARS-CoV-2-infected Golden Syrian hamsters with sulfonated Calpeptin at a dose of 1 mg/kg body weight reduces the viral load in the trachea. Despite a higher risk of side effects, an intrinsic advantage in targeting host proteins is their mutational stability in contrast to highly mutable viral targets. Here we show that the inhibition of cathepsins, a protein family of the host organism, by calpeptin is a promising approach for the treatment of SARS-CoV-2 and potentially other viral infections.
Impact Factor
Scopus SNIP
Altmetric
5.900
0.000
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Language english
Publication Year 2023
HGF-reported in Year 2023
ISSN (print) / ISBN 2399-3642
e-ISSN 2399-3642
Journal Communications Biology
Quellenangaben Volume: 6, Issue: 1, Pages: , Article Number: 1058 Supplement: ,
Publisher Springer
Publishing Place London
Reviewing status Peer reviewed
Institute(s) Institute of Virology (VIRO)
POF-Topic(s) 30203 - Molecular Targets and Therapies
Research field(s) Immune Response and Infection
PSP Element(s) G-502700-001
G-502700-010
DOI 10.1038/s42003-023-05317-9
Scopus ID 85174463058
PubMed ID 37853179
Erfassungsdatum 2023-11-28
[➜Report correction]